Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
What Abbott Laboratories (ABT)'s Oncology Test Integration Into OncoEMR Means For Shareholders
Abbott Laboratories recently integrated its Precision Oncology portfolio into Flatiron’s OncoEMR platform, allowing for digital ordering and result delivery of key oncology tests in over 1,600 U.S. community cancer centers. This integration is expected to enhance test utilization and streamline clinical workflows for Abbott (ABT), reinforcing its diagnostics segment. Despite potential benefits from this and other integrations like the Libre CGM data with Epic, the company still faces challenges such as margin pressure from tariffs and pricing in China and competitive pressures in diagnostics and diabetes care.